Navigating material demands of next-gen CGTs

The science behind cell and gene therapies continues to advance, with a growing list of novel approaches and new indications approved each year. But as these medicines evolve, so do material demands. Increasingly complex therapies demand high-quality reagents, antibodies, and specialty materials essential to moving products through development and into commercial stages. At each stage, researchers and drug developers must make supply decisions that balance cost and logistical constraints against scientific rigor and regulatory expectations.

Strategic suppliers can help drug developers make the right choices — from raw materials to critical biochemicals — to improve program continuity, the robustness of analytical data, and overall development efficiency.

The realities of global supply sourcing

Every phase of CGT research depends on countless specialized tools and materials shipped from all over the world. This creates inherent instability for much of the supply chain, as prices and availability are subject to changes outside of suppliers’ control, such as tariffs, trade policies, or geopolitical difficulties. Furthermore, deciding where to source key materials can have implications for regulatory alignment in later stages. Regulatory demands and manufacturing standards may differ slightly between regions, and drug developers may struggle to align these differences at later stages of their program.

These obstacles can be especially difficult for small and mid-sized drug developers, which face intense pressure to balance time to market with financial constraints and may lack the resources or experience to build an end-to-end plan that efficiently supports products through commercialization. The right supplier can provide strategic support by clarifying the manufacturing footprint, quality systems, and alignment with local regulatory standards. With this foundation, developers can better navigate supply chain logistics, reducing unexpected disruptions to manufacturing and clinical timelines.

Strategic supplier selection

The supply needs of a CGT will vary significantly throughout the product’s life cycle. Early stages can maximize cost efficiency, while late stages must focus on regulatory readiness. A deep understanding of supply needs and the ability to seamlessly transition between phases is critical to a program’s success. Developers should select suppliers that understand these nuances, ensure quality at every stage, and are able to grow as the product needs evolve.

This concept may seem straightforward, but the details can be complex in practice. Developers must consider the increasing levels of technical and documentation needs that will arise as a program scales. Additionally, they must be confident that their chosen supplier operates with sufficient transparency and quality management to fuel their program through to commercial development.

GMP-grade components are a significant investment, and drug developers often rely on more cost-effective, research-grade solutions for early development stages. For many less-established developers, however, it can be challenging to navigate these decisions while ensuring regulatory preparedness. In this regard, a good supplier is more than a vendor; they’re a strategic partner and experienced consultant. A strong supply partnership should begin with a detailed conversation about the program’s needs and how the supplier can provide the appropriate support at every stage and scale.

Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients. Critical component suppliers can support program success by providing solutions that balance cost efficiency, regulatory rigor and scalability, while equipping developers with the knowledge needed to avoid timeline delays. With the strategic support of a reliable supplier, developers can focus more time and resources on delivering therapies to patients.